Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01317927 · ClinicalTrials.gov registry record · Phase 1
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
A Phase 1 study, sponsored by Spectrum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01317927 is a Phase 1 study that has completed, run by Spectrum Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT01317927, a Phase 1 study, has completed, sponsored by Spectrum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m². Pharmacokinetic evaluation of belinostat 1,000 mg/m² and metabolites in the presence of warfarin 5 mg.
Interventions
- DRUG Belinostat, Warfarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-12 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01317927
The ClinicalTrials.gov registry entry for NCT01317927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spectrum Pharmaceuticals, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belinostat, Warfarin is the first listed.
NCT01317927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01317927 about?
NCT01317927 is a clinical study titled "A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies". The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m². Pharmacokinetic evaluation of belinostat 1,000 mg/m² and metabolites in the presence of warfarin 5 mg.
What is the current status of trial NCT01317927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-12. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01317927?
The interventions under investigation include: Belinostat, Warfarin (DRUG).
Who is sponsoring clinical trial NCT01317927?
This trial is sponsored by Spectrum Pharmaceuticals, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.